2025 - Organization of Congresses, listed by Name
Organisationskomitee
2025 - Committees/Groups with Respect to Research
SPO-NDS Executive Board
2025 - Management Tasks
Ärztliche Leitung Tumorzentrum
2025 - Ad Hoc Reviewer, listed by Journal Name
Peer reviews 2022-2025: ctDNA detection sanctuary sites, Quality of PRO reporting myeloma RCTs
2025 - National Conferences and Events, listed by Name
Invited Speaker
2025 - Organization of Congresses, listed by Name
Scientific Committee
2025 - Events for the Public (Uni-Nacht)
Organisation und Moderation
2024 - Ad Hoc Reviewer, listed by Journal Name
Peer reviews 2020-2025: Methotrexate-refractory PCNSL, CNS lymphoma diagnostics, MTX clearance outcomes, Thiotepa conditioning, CNS lymphoma study
2024 - Ad Hoc Reviewer, listed by Journal Name
Peer reviews 2021-2025: MYD88 detection, Rituximab-MTX combination, Cardiovascular post-ASCT, Primary CNS T-cell lymphoma
2024 - National Conferences and Events, listed by Name
Invited Speaker - SSMO Highlights of the Year / Lymphoma
2024 - Ad Hoc Reviewer, listed by Journal Name
Peer reviews 2024: High-dose cytarabine first-line therapy in MTX-ineligible patients (2 rounds)
2024 - Ad Hoc Reviewer, listed by Journal Name
Peer reviews 2021-2024: Clinical trial uncertainties FDA labeling, Real-world oral targeted cancer drugs
2024 - Ad Hoc Reviewer, listed by Journal Name
Peer review 2021: Thyroid cancer incidence and mortality trends Canton Zurich
2023 - Ad Hoc Reviewer, listed by Journal Name
Peer review 2023: R2-MTX regimen efficacy in primary CNS lymphoma with ctDNA dynamics
2023 - Further Activities
Chair Oral presentations Clinical hemato-oncology (SOHC 2023)
2023 - National Conferences and Events, listed by Name
SAMO - Workshop: Invited Talk on Subgroup Analyses in Lymphoma Trials
2023 - Ad Hoc Reviewer, listed by Journal Name
Peer reviews 2022-2023: MYC/BCL2 double expression impact, PROs after HD-ASCT in PCNSL
2023 - Ad Hoc Reviewer, listed by Journal Name
Peer review 2023: Cancer incidence and mortality in type 1 diabetes UK follow-up
2023 - Ad Hoc Reviewer, listed by Journal Name
Peer review 2023: Geriatric assessment dose modification study protocol primary CNS lymphoma
2023 - Ad Hoc Reviewer, listed by Journal Name
Cancer incidence and mortality in 23,000 patients with type 1 diabetes in the UK: long-term follow-up
2023 - Ad Hoc Reviewer, listed by Journal Name
Study protocol for a multicentre, non-randomised, phase 2 study of multidrug chemotherapy with high-dose methotrexate, procarbazine, and vincristine followed by reduced-dose, whole-brain radiation and high-dose cytarabine therapy for primary central nervous system lymphoma in elderly patients with d
2023 - Ad Hoc Reviewer, listed by Journal Name
Outcomes Associated with Time to High-Dose Methotrexate Clearance in Patients with Central Nervous System Lymphoma
2022 - Ad Hoc Reviewer, listed by Journal Name
Detection of circulating tumor DNA in plasma of patients with primary large B-cell lymphoma of the sanctuary sites by digital droplet PCR
2022 - Ad Hoc Reviewer, listed by Journal Name
Patient Reported and Clinical Outcomes After High-dose Chemotherapy and Autologous Stem Cell Transplantation in PCNSL
2022 - Ad Hoc Reviewer, listed by Journal Name
CAR-T Use in Solid Organ Transplant Recipients: a Case Report and Literature Review
2022 - Ad Hoc Reviewer, listed by Journal Name
FDG PET/CT radiomics DLBCL progression prediction studies
2022 - Ad Hoc Reviewer, listed by Journal Name
Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features
2022 - Ad Hoc Reviewer, listed by Journal Name
Considerations when introducing electronic patient-reported outcome data capture in multicentre oncology randomised controlled trials COMMENT
2022 - Ad Hoc Reviewer, listed by Journal Name
CAR-T in solid organ transplant, T-cell responses SARS-CoV-2 Omicron
2022 - Ad Hoc Reviewer, listed by Journal Name
Peer reviews 2022: HD-chemotherapy with ASCT in relapsed/refractory primary CNS lymphoma
2022 - Ad Hoc Reviewer, listed by Journal Name
Peer reviews 2022: Electronic PRO data capture, Operational complexity platform trials, Protocol reviews
2022 - Ad Hoc Reviewer, listed by Journal Name
Peer review 2022: Early discontinuation hematologic cancer clinical trials
2021 - Ad Hoc Reviewer, listed by Journal Name
Peer review 2021: Oncology drug clinical benefit and time to reimbursement
